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Autoantibodies against many proteins are common in sera from patients with various types of cancer. These antibodies are
sometimes involved in the development of conditions associated with cancer, such as paraneoplastic neurologic disorders. We used a
human brain cDNA expression library and serum from a paraneoplastic neurologic disorder patient to search for new autoantigens in
the nervous system. Pyridoxal phosphatase was identified as a novel autoantigen. Expression studies showed that pyridoxal
phosphatase was strongly expressed in various parts of the central nervous system. Sera contained antibodies against pyridoxal
phosphatase in 22 of 243 (9.1%) patients with lung cancer and eight of 113 (7.1%) with other forms of cancer vs two of 88 (2.3%)
healthy control subjects. In addition, 2–4% of patients with different autoimmune diseases had autoantibodies against pyridoxal
phosphatase. None of the antipyridoxal phosphatase-positive patients were known to have a paraneoplastic neurologic disorder.
Hence, autoantibodies against pyridoxal phosphatase correlate with cancer but not necessarily with the subset of patients with
paraneoplastic neurological disorders although serum from such a patient was used to screen the cDNA library. This study showed
that yet another enzyme involved in pyridoxal 50-phosphate metabolism is an autoantigen. Thus, pyridoxal 50-phosphate seems to be
a common denominator for autoantigens involved in autoimmune diseases.
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Antibodies against nontissue specific intracellular or cell-surface
proteins are seen in several types of cancer, such as antibodies
against p53 (Crawford et al, 1982), oncogene products such as ras
(Cheever et al, 1995), cellular proteins such as p62 (Zhang et al,
1999) and cell cycle proteins such as cyclin B1 (Covini et al, 1997).
Other malignant conditions are characterised by autoantibodies
against tissue-restricted proteins, as seen in patients with
paraneoplastic neurologic disorders (PND). These patients pro-
duce antibodies and cytotoxic T cells that target neuron-specific
proteins abnormally expressed in non-neuronal tumours causing
neuronal injury (Dalmau and Posner, 1997; Bataller and Dalmau,
2003). The pathogenic role of onconeuronal autoantibodies is often
unclear. In other cases, such as Lambert–Eaton myasthenic
syndrome, antibodies are directly involved in pathogenesis, such
as by blocking voltage-gated calcium channels and causing
neuromuscular conduction blockade (Lang et al, 1981).
Detection of circulating autoantibodies signals the presence of
malignant disease, often at an early stage (Trivers et al, 1995,
1996), and assay of cancer-associated antibodies can be used in
diagnosing cancer. Further, an immune response against the
tumour should theoretically help in controlling tumour growth.
Souza et al (2003) have recently shown that patients with previous
autoimmune thyroid disease and well-differentiated thyroid cancer
have a better prognosis than those without signs of thyroid
autoimmunity.
By using serum from a patient with known PND, we screened a
human brain cDNA expression library to identify novel cancer-
related or paraneoplastic autoantigens. One of the positive clones
was identified as pyridoxal phosphatase (PDXP) (GenBank
accession number AY125047 and BC000320) (Jang et al, 2003).
This enzyme dephosphorylates pyridoxal 50-phosphate (PLP), an
important cofactor for enzymes involved in vitamin B metabolism
and in neurotransmitter biosynthesis.
METHODS AND SUBJECTS
Subjects
Sera were obtained from 243 patients with lung cancer, 113 with
different other types of cancers, 47 with multiple sclerosis (MS), 47
with type 1 diabetes, 72 with autoimmune Addison’s disease or
autoimmune polyendocrine syndromes (APS) and 88 healthy
blood donors.
Screening of the cDNA expression library
A human brain l TriplEx cDNA expression library (human brain
50-Stretch Plus cDNA Library, Clontech, Palo Alto, CA, USA) was
screened with serum from a patient with ovarian cancer and
paraneoplastic cerebellar degeneration containing Yo antibodies
using the method described by Rorsman et al (1995). Briefly,
bacteria and the cDNA library were mixed on a Petri dish
containing NZY agar. After about 3.5h of culture, plaque appeared
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yon the dish. Plaques were copied onto a Hybond C nitrocellulose
membrane (Amersham Pharmacia Biotech, Uppsala, Sweden)
containing isopropyl-b-D-thiogalactoside (Sigma-Aldrich, Stein-
heim, Germany). Sera and secondary alkaline phosphatase-
conjugated antibodies were added to the filter, followed by 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BioR-
ad, Sundbyberg, Sweden) to detect immune complexes. Positive
clones were rescreened until pure isolates were obtained and
thereafter sequenced and identified by a BLAST search (http://
www.ncbi.nlm.nih.gov/BLAST). Full-length clones were ordered
when needed from the I.M.A.G.E. Consortium (http://image.llnl.-
gov).
Radioimmunoassay (RIA)
The full-length coding cDNA was amplified by polymerase chain
reaction using a forward linker-primer containing an NdeI
restriction site (50-GGAATTCCATATGGCGCGCTGCGAGAGGCT-
30) and a reverse linker-primer containing a BamHI restriction
site (50-GGCGGATCCGGCTCAGTCCTCCAACCCCTCTGTCAA-30).
The cDNA was then ligated into the NdeI and BamHI restriction
sites of pET-19b (Novagen Inc., Madison, USA) and expressed as a
10  His-tag fusion protein in the in vitro TnT transcription–
translation coupled (ITT) system from Promega (Promega, Leiden,
the Netherlands) in the presence of [
35S]methionine (cell labelling
grade, Amersham Pharmacia Biotech) and screened by RIA
(Falorni et al, 1995). Titre of antibodies was calculated as relative
values compared with standard positive and negative controls
((cpm subject X–cpm negative standard)/(cpm positive standard–
cpm negative standard) 1000). The ‘normal level’ of autoanti-
bodies against this protein in sera was estimated by calculating the
mean of index values for 88 healthy blood donors and adding 3
standard deviations.
Protein expression and purification
The protein was expressed as a 10  His-tag fusion protein by the
vector pET19b in the Escherichia coli strain Rosetta (DE3) pLysS
(Novagen, Madison, WI, USA). In total, 500ml of Luria-Bertani
medium containing 50mgml
 1 ampicillin was inoculated with 4ml
of an overnight culture of bacteria generated from a single colony
of freshly transformed cells and incubated at 371C. The bacterial
culture was grown at 371C, and protein expression was induced
with 1mM isopropyl-b-D-thiogalactoside at an optical density at
600nm of 0.9. The cells were harvested 3.5h later by centrifuga-
tion. Inclusion bodies were purified in the presence of complete,
EDTA-free Protease Inhibitor Cocktail Tablets (Roche, Basel,
Switzerland) using the B-PER Bacterial Protein Extraction Reagent
(Pierce, Rockford, IL, USA) according to the manufacturer’s
protocol. Inclusion bodies from a 75-ml culture were dissolved in
2mlof6M guanidine-HCl, 20mM NaH2PO4, 500mM NaCl, pH 7.8
before adding 10ml of 8 M urea, 20mM NaH2PO4, 500mM NaCl, pH
7.8 (buffer A). The solution was then centrifuged at 20000 g and
filtered through a 0.45-mm syringe filter followed by nickel chelate
chromatography using the A ¨KTAprime chromatography system
and a 1-ml HiTrap Chelating HP column (Amersham Pharmacia
Biotech) under denaturing conditions. Briefly, the solubilised
inclusion bodies were loaded onto the column followed by washing
with 40 column volumes of buffer A containing 20mM imidazol.
The protein was eluted at low pH by exchanging the wash buffer
with a buffer containing 8 M urea, 20mM NaH2PO4, 500mM NaCl,
pH 3.5 with a gradient from 0 to 100% over 20 column volumes.
The protein purity was evaluated by sodium dodecyl sulfate–
polyacrylamide gel elecrophoresis (SDS–PAGE) followed by
Coomassie blue staining. The concentration was determined by
the Bradford protein assay (BioRad) using bovine serum albumin
(BSA) as standard according to the protocol of the manufacturer.
Rabbit PDXP antiserum
Purified PDXP was dialysed against sterile phosphate-buffered
saline (PBS). Two female outbred rabbits were immunised
intradermally with about 50mg of purified protein emulsified 1:1
in Freund’s complete adjuvant. The rabbits were boosted with
about 50mg of protein emulsified 1:1 in Freund’s incomplete
adjuvant on days 14, 28, 56 and 86 after the primary immunisation.
After reactivity towards the protein antigen was verified by RIA of
radiolabelled protein expressed by ITT (described above) and by
Western blot (described below), the rabbits were terminally bled
on day 96 and serum was collected.
Western blot
Recombinant PDXP (about 15mg) was incubated in 4  sample
buffer and 10  reducing agent and applied to the large well on a
4–12% NuPAGE MOPS Bis-Tris gel (Invitrogen, Merelbeke,
Belgium). The molecule markers used were the high-range rainbow
molecular weight marker (Amersham Pharmacia Biotech) for
radiolabelled samples and the Seeblue Plus 2 prestained standard
(Invitrogen) for nonlabelled samples. The proteins were blotted
onto a Hybond P PVDF membrane (Amersham Pharmacia
Biotech) and incubated with sera from 24 cancer patients that
were positive for anti-PDXP in RIA or immunised rabbit-serum
diluted 1:100 in blocking buffer (PBS with 4% fat-free dry milk)
and then with alkaline phosphatase-conjugated rabbit anti-human
IgG (Sigma-Aldrich) and goat anti-rabbit IgG (Southern Biotech-
nology, Birmingham, AL, USA), diluted 1:3000 in blocking buffer.
The substrate for alkaline phosphatase was 5-bromo-4-chloro-3-
indolyl phosphate/nitro blue tetrazolium (BioRad).
Immunohistochemistry
We used autopsy material from a 69-year-old man, otherwise
healthy, who had died from sudden cardiac arrest 24h previously.
Tissue from cerebrum, cerebellum, liver, kidney, spleen, heart,
lung and muscle was taken from 2–3 locations in each organ,
snap-frozen in isopenthane cooled in liquid nitrogen and stored at
 801C until use. A total of 8mm thick cryostat sections were
incubated with the preimmunised or immunised rabbit sera
against PDXP diluted 1:100 in PBS and then with Alexa Fluor
goat anti-rabbit IgG (Molecular Probes, Eugene, OR, USA) diluted
1:100 in PBS. Analysis used a LEICA fluorescence microscope. In
some experiments, sections of human brain were stained with
rabbit anti-PDXP diluted 1:100 in PBS followed by peroxidase-
labelled anti-rabbit antibody and analysis by light microscopy.
Tissue sections were incubated without prior fixation, as we
experienced that fixation with acetone or formaldehyde prior to
primary incubation did not result in enhanced staining.
Northern blot
In total, 20mg of total RNA from rat cerebellum purified by the
RNeasy mini kit (Qiagen, Hilden, Germany), rat brain (Clontech)
and of a pool of total RNA from a wide selection of human tissues
(Human Reference total RNA; Clontech) were denatured, electro-
phoresed on a denaturing 1.2% formaldehyde agarose gel and
blotted onto a Hybond N nylon membrane (Amersham Pharmacia
Biotech) by capillary blotting in the presence of saline sodium
citrate buffer (10  SSC; 1.5 M NaCl, 0.15 M sodium citrate, pH 7.0).
The membrane was washed in a buffer containing 1.6  SSC and
0.2 M Tris-HCl pH 7.2 and baked at 801C for 15min, and the RNA
was crosslinked to the membrane at 120mJ using Stratalinker 1800
UV (Stratagene, La Jolla, CA, USA). Full-length PDXP cDNA
(20ng) was labelled with 4mlo fa-
32P-dCTP (3000mCimmol
 1,
Perkin-Elmer, Boston, MA, USA) using the Megaprime kit
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y(Amersham Pharmacia Biotech) and purified over a Sephadex
G-50 (Amersham Pharmacia Biotech). The blot was wetted in 2 
SSC and prehybridised for 1h at 651C in 16ml of hybridisation
buffer containing 2mgml
 1 bovine serum albumin, 2mgml
 1
Ficoll 400, 2mgml
 1 polyvinylpyrrolidone K25, 0.5 M NaH2PO4,
14mgml
 1 SDS, 1mM EDTA, 5mg of heat-denatured, sheared
salmon sperm DNA (Sigma-Aldrich) and 30mg of heat-denatured
human Cot-1 DNA (Invitrogen). The probe was denatured by heat
in 1ml of hybridisation buffer, added to the hybridisation solution
used for prehybridisation and incubated with the membrane at
651C overnight. The hybridised membrane was then washed four
times at 651C for 30min in a washing buffer (20mM NaH2PO4 pH
7.2 and 5mgml
 1 SDS) and exposed to Kodak BioMax MS Film
(Eastman Kodak Company, New Haven, CT, USA) at  801C for 2
days using BioMax TranScreen HE intensifying screen (Eastman
Kodak Company).
Expression studies
Gene expression in human tissues of the isolated cDNA was
determined by hybridising cDNA with the Multiple Tissue
Expression Array (Clontech). Full-length coding cDNA was
labelled with a-
32P-dCTP, hybridised against the Multiple Tissue
Expression Array and developed as described for Northern blots.
In addition, rabbit PLP phosphatase antiserum (described above)
diluted 1:500 was applied to the Newborn Rat Brain Protein
Explorer (Alpha Diagnostic International, San Antonio, TX, USA),
a commercial ready-made membrane containing brain proteins
from rats. Hybridisations were detected using chemiluminescence
following the instructions of the manufacturer, except that donkey
anti-rabbit horseradish peroxidase-coupled IgG (HþL) (Jackson
ImmunoResearch, West Grove, PA, USA) and the SuperSignal
West Femto Maximum Sensitivity Substrate chemiluminescence
kit (Pierce) were used for detection instead of the reagents in the
kit. The membrane was exposed for 15min on a IMAGE Station
2000R (Eastman Kodak Company).
Statistical analysis
Differences between groups were assessed using the Pearson w
2
test.
Ethical considerations
The study has been carried out with ethical committee approval.
For animal experiments, United Kingdom co-ordinating commit-
tee on cancer research (UKCCCR) guidelines for the Welfare of
Animals in Experimental Neoplasia were followed (Workman
et al). The study was performed according to the Declaration of
Helsinki.
RESULTS
Identification of a novel autoantigen
Screening the cDNA library with the PND serum revealed a
positive clone that was isolated and sequenced. The nucleotide
sequence showed that the clone was identical to a truncated form
of PDXP that covered amino-acid codons 122–297 (GenBank
accession number AY125047) (Fonda, 1992; Gao and Fonda,
1994a–c; Fonda and Zhang, 1995; Jang et al, 2003). Full-length
cDNA for PDXP was ordered from the I.M.A.G.E Consortium and
subcloned into the pET19b vector. The full-length coding sequence
contained 891 nucleotides and encoded a protein of 297 amino
acids with a molecular weight of 32kDa.
Expression of recombinant PDXP and production of
antibodies against PDXP
We expressed PDXP as
35S-labelled protein using ITT (Figure 1A).
The protein was also expressed in E. coli and purified to about 95%
as judged by SDS–PAGE (Figure 1B). The molecular weight of the
ITT-expressed protein correlated with the weight of the bacterially
66 kDa
45 kDa
30 kDa
20 kDa
62 kDa
49 kDa
38 kDa
28 kDa
AB
Figure 1 (A) SDS–PAGE of in vitro coupled transcribed and translated
35S-labelled PDXP. (B) SDS–PAGE of 2mg E. coli-expressed purified
PDXP detected by Comassie blue staining.
A BC
5 kb
2 kb
Figure 2 Northern blot of PDXP cDNA. The cDNA was labelled
with a-
32P-dCTP and hybridised against total RNA electrophoresed on a
formaldehyde agarose gel. (A) Human reference total RNA. (B) Rat brain
total RNA. (C) Rat cerebellar total RNA.
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immunise a rabbit in order to achieve antibodies against PDXP.
One immunised rabbit produced a high-titre antiserum against
PDXP as assessed by RIA and Western blot, whereas serum from
the preimmunised rabbit did not bind the protein.
Tissue expression of PDXP
Northern blot of radioactive-labelled full-length PDXP against
RNA pools of different origins revealed that the molecular
weight of the messenger RNA was about 2kb (Figure 2)
(Jang et al, 2003). The results from mRNA multitissue expression
level analysis of PDXP using polyA RNA dot blot indicated
that the PDXP gene was strongly expressed in different parts of the
central nervous system and also to some extent in testis, liver,
kidney and cancer cell lines (Figure 3). Most of the other tissues
represented on the blot also expressed PDXP but to a lesser degree
than in the neuronal tissue. These results were supported by
results obtained from analysis of the brain ReadyBlot explorer kit
(data not shown).
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Figure 3 Expression of PDXP in various human normal tissues and cancer cell lines. The PDXP cDNA was labelled with a-
32P-dCTP and hybridised
against the Multiple Tissue Expression Array consisting of normalised, polyA RNA spotted on a nylon membrane as denoted in (B) PDXP transcripts are
most abundant in the nervous system (columns 1–3) (A). The cDNA probe hybridised with E. coli DNA, probably due to several identical nucleotide
stretches.
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autoimmune disease and controls
Altogether, 22 of 243 (9.1%) lung cancer patients and eight of 113
(7.1%) patients with various other types of cancer had auto-
antibodies against PDXP (Figure 4), whereas two of 88 (2.3%) sera
from healthy controls revealed reactivity (P¼0.046 when compar-
ing all cancer patients with healthy controls). In addition, one of 47
(2.1%) patients with type 1 diabetes (three of 72 (4.1%) patients
with autoimmune Addison’s disease or APS and two of 47 (4.5%)
MS patients had autoantibodies against PDXP (Figure 4) (P¼0.008
when comparing all four control groups with all cancer patients).
Clinical data were only available from some of the cancer patients
with PDXP antibodies, and no PND was discovered in these.
Onconeuronal antibodies (anti-Hu) were detected in five of the
anti-PDXP positive sera from the patients with lung cancer using
immunofluorescence and immunoblot. None of the antibody-
positive patients with Addison’s disease, APS, diabetes or MS had
known malignant disease. Among the patients with sera containing
PDXP antibodies detected by RIA, five of 15 (33%) patients with
lung cancer and three of eight (38%) patients with various types of
cancer recognised PDXP by Western blot.
Immunohistochemistry
The rabbit antisera against PDXP stained human cerebrum and
cerebellum but not liver, spleen, lung, heart, kidney and muscle
(data not shown). Anti-PDXP stained the cytoplasm of microglia
(Figure 5) and astrocytes. Neurons also stained weakly.
DISCUSSION
This study identified PDXP as a novel autoantigen associated with
various types of cancer, including lung cancer. In total, 9% of
patients with lung cancer and 7% of patients with other types of
cancer revealed reactivity against PDXP vs 2% among healthy
controls. In the immunoprecipitation experiments, some sera
reacted with native proteins and failed to recognise proteins that
had been frozen (data not shown). This may imply that the protein
changed its conformation after freezing and thawing and that
autoantibodies recognise conformational epitopes. This specula-
tion is supported by the finding that only a subgroup of the
patients positive in the RIA assay showed reactivity in Western
blot. RIA seems to be a more sensitive method for detecting
autoantibodies, similar to the findings with anti-Hu (Storstein et al,
2004) and antiinsulin (Sodoyez-Goffaux et al, 1988). Five of the
lung cancer patients positive for anti-PDXP also had circulating
Hu-antibodies but not clinically evident PND. Onconeuronal
antibodies were not detected in any of the other anti-PDXP
positive sera. Our findings therefore indicate that PDXP is
associated with cancer and not with PND, but the latter association
cannot be ruled out.
Autoantibodies against several different proteins are frequent in
cancer patients, and most appear in a wide variety of types of
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Figure 4 PDXP autoantibody analysis using immunoprecipitation assays. The figure shows the distribution of index values for the different groups of
subjects used in this study. PDXP antibody reactivity is given as indices relative to a positive (patient serum) and negative control (pool of sera from healthy
individuals) ((cpm subject X cpm negative standard)/(cpm positive standard cpm negative standard) 1000). The cutoff value for identifying positive
samples for autoantibodies against PDXP was 279. Lanes 1–14: sera from patients with tumours of different origins. 1: lymphoma, 2: mammary, 3: bladder, 4:
ovary, 5: uterus, 6: testis, 7: skin (malignant melanoma), 8: prostate, 9: kidney, 10: colon, 11: bile duct, 12: rectum, 13: other, 14: lung. Lanes 15–18: sera from
patients with other autoimmune diseases and controls. 15: Addison’s disease or APS type II, 16: type 1 diabetes, 17: multiple sclerosis and 18: blood donors.
Figure 5 Anti-PDXP-stained cytoplasm of microglia of human brain
sections in immunohistochemical experiments (400 ). Examples of
stained cells are marked with *.
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findings of anti-PDXP. Autoantibodies against the cell cycle
checkpoint protein p53, for example, are found in 9–20% of
human cancer patients with a specificity of 96% (Soussi, 2000). Hu
and VGCC antibodies were not related to improved survival in
patients with small-cell lung cancer (Monstad et al, 2004). The
effects of circulating autoantibodies against PDXP are still unclear.
Future studies on more well-defined patient materials should
elucidate the sensitivity and specificity of the association between
antibodies against PDXP and cancer. Our finding of an increased
frequency among patients with Addison’s disease, APS and MS
compared with controls may imply other associations than cancer.
It would also be interesting to determine whether anti-PDXP in
patients affects the course and prognosis of malignant disease.
The recent study by Jang et al (2003) revealed that the
expression of PDXP is ubiquitous, although with higher levels in
the central nervous system, testis and liver. This is in agreement
with our results. We found high expression in the central nervous
system but also in a number of cancer cell lines, which could
explain why PDXP becomes an autoantigen in patients with
cancer. The PLP level in various tissues is regulated by several
enzymes: PDXP, pyridoxal kinase, pyridoxamine-50-phosphate
oxidase and various binding proteins (Anderson et al, 1974; Li
et al, 1974; Harris, 1990; Fonda, 1992). The brain contains an
especially high concentration of PLP, and this is where the highest
expression of PDXP is. More than 140 distinct enzymatic reactions
depend on PLP according to the Enzyme Commission (http://
www.chem.qmul.ac.uk/iumbm/enzyme) (Percudani and Peracchi,
2003), including many enzymes that participate in the biosynthesis
of important neurotransmitters. Examples of the latter are
glutamate decarboxylase participating in the synthesis of GABA
and aromatic L-amino acid decarboxylase participating in the
biosynthesis of catecholamines and serotonin. Interestingly, these
enzymes have recently been found to be autoantigens in nervous
system and endocrine diseases. Antibodies against glutamate
decarboxylase (Lindefors, 1993) are found in type 1 diabetes
(Baekkeskov et al, 1990), stiff-man syndrome (Solimena et al,
1990) and APS type I (Velloso et al, 1994). Autoantibodies against
aromatic L-amino acid decarboxylase (Rorsman et al, 1995),
histidine decarboxylase (Skoldberg et al, 2003) and cysteine
sulfinate decarboxylase (Skoldberg et al, 2004) are all found in
patients with APS type I. We have now shown that another enzyme
related to PLP is an autoantigen, making PLP a common
denominator for enzymes targeted by the immune system in
endocrine and nervous system autoimmune diseases.
The reason why the immune system recognises PDXP and other
PLP-associated autoantigens as non-self remains obscure. PLP,
which is the coenzymatically active form of vitamin B6 (pyridox-
ine), is reported to suppress tumorigenesis, such as in colon cancer
(Matsubara et al, 2003). The mechanisms behind the chemopre-
ventive effect of vitamin B6 probably combine inhibitory effects on
cell proliferation, oxidative stress and angiogenesis. One theory is
that some tumours express elevated levels of PDXP to overcome
the suppressive effect of vitamin B6. The increased expression
might induce a break in immune tolerance against PDXP. The
Multiple Tissue Expression Array revealed that some cancer cell
lines express PDXP. PLP has also recently been suggested to have
immunomodulatory properties because it binds very tightly to the
D1 domain of CD4 on T cells, thereby interfering with proper
interaction between CD4 and the major histocompatibility
complex class II (Salhany and Schopfer, 1993). Lack of interaction
leads to T-cell apoptosis and anergy to autoantigens (Namazi,
2003). One might speculate increased expression of PDXP degrade
PLP, thereby facilitating tumour growth, but this could also lead to
an enhanced immune response against the tumour.
In conclusion, PDXP is a novel autoantigen associated with
cancer. PLP seems to be a common denominator for autoantigens
involved in nervous system and endocrine autoimmune diseases.
The clinical implications of anti-PDXP remain to be defined.
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